Stemline Therapeutics to Present at Upcoming Investor Conferences
September 20, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
September 11, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 08, 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
August 30, 2017 18:10 ET
|
Stemline Therapeutics
NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 14, 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Reports Second Quarter 2017 Financial Results
August 08, 2017 07:00 ET
|
Stemline Therapeutics
NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
June 23, 2017 09:36 ET
|
Stemline Therapeutics
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference
June 06, 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting
May 18, 2017 07:30 ET
|
Stemline Therapeutics
NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
Stemline Therapeutics Reports First Quarter 2017 Financial Results
May 10, 2017 17:12 ET
|
Stemline Therapeutics
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...